Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

Introduction

For the past 15 years, vascular endothelial growth factor tyrosine kinase inhibitors (VEGF TKIs; sunitinib and pazopanib) were standard first-line treatment in metastatic renal cell carcinoma (mRCC). A phase-III randomized controlled trial included 750 treatment-naive patients comparing sunitinib vs interferon alpha and showed higher objective response rate (ORR; 31 vs. 6%, p < 0.001) and higher progression-free survival (PFS) rate with sunitinib as compared with interferon alpha (11 vs. 5 months, hazard ratio [HR] = 0.42, 95% confidence interval [CI]: 0.32–0.54, p < 0.001). There was no complete response.[1]

Updated analysis of the study showed response rate of 47 versus 12% (p < 0.001), improved PFS (11 vs. 5 months, p < 0.001), and improved overall survival (OS; 26.4 vs. 21.8 months, HR = 0.821, 95% CI: 0.673–1.001, p = 0.51) of sunitinib as compared with interferon alpha.[2]

Another phase-III placebo-controlled trial randomized 435 treatment-naive or cytokine-pretreated patients into pazopanib versus placebo arm. ORR (30 vs. 3%, p < 0.001) and median PFS (9.2 vs. 4.2 months, HR = 0.46, 95% CI: 0.34–0.62, p < 0.001) were higher in the pazopanib as compared with placebo arm.[3]

Cabozantinib was compared with sunitinib in a phase-II randomized study including 157 intermediate- and poor-risk international mRCC database criteria (IMDC) patients.[4] ORR was 33% (95% CI: 23–44) for cabozantinib versus 12% (95% CI: 5.4–21) for sunitinib. Cabozantinib significantly improved the median PFS 8.2 versus 5.6 months as compared with sunitinib (HR = 0.66; 95% CI: 0.46–0.95; one-sided p = 0.012).

There were no studies of VEGF TKI combinations in first-line therapy of mRCC before the arrival of immunooncology (IO) drugs into the picture.

Nivolumab was the first immunotherapy drug approved in second-line therapy after failure of VEGF TKI. Five out of six IO drug combinations have been recently Food and Drug Administration (FDA) approved in first-line mRCC treatment. A summary of these six trials have been provided in [Table 1].[5] [6] [7] [8] [9] [10]

Table 1 The various studies comparing outcomes of Immunotherapy and VEGF TKIs in patients with mRCC

Study (ref.)	Intervention	No. Of patients	ORR	CR	mPFS (months)	OS (months)	Comment
CheckMate 214[5]	Ipilimumab–nivolumab Sunitinib	550 446	65% 50%	10% 1%	11.6 8.4 (p = 0.02)	48 26.6 (HR = 0.65, 95% CI: 0.54–0.78)	Study showed OS advantage in intermediate- and poor-risk patients (and not in favorable risk)
KEYNOTE 426[6]	Axitinib–pembrolizumab Sunitinib	432 429	59.3% (95% CI: 54.5–63.9) 35.7% (95% CI: 31.5–40.4), p < 0.001	5.5% 1.9%	15.1 (95% CI: 12.6–17.7) 11.1 (95% CI: 8.7–12.5)	Not reached Not reached	Updated result: at a minimum follow-up of 23 months, median OS is not reached with pembrolizumab–axitinib vs. 36.7 month with Sunitinib. No OS advantage was seen in favorable risk disease but there was PFS and ORR benefit. A post hoc analysis found that achieving CR improved the chances of overall survival in both arms
JAVELIN Renal 101[7]	Avelumab–axitinib Sunitinib	442 444	51.4%(95% CI: 46.6–56.1) 25.7% (95% CI: 27.1–30.0)	3.4% 1.8%	13.8 (95% CI: 11.1 to could not be estimated 8.4, HR = 0.69; 95% CI: 0.56 to 0.84; p < 0.001		PDL1 positive population, similar result as overall population
IMmotion 151[8]	Atezolizumab–bevacizumab Sunitinib	454 461			PFS in PDL1 positive population 11.2 7.7, HR = 0.74, 95% CI: 0.57–0.96, p = 0.0217		In ITT population median OS had a HR of 0.93 (0.76–1.14)
CheckMate9ER[9]	Cabozantinib–nivolumab Sunitinib	323 328	55.7% (95% CI: 50.1–61.2) 27.1% (95% CI: 22.4–32.3) (p < 0.0001	8% 4%	16.6 8.3 (HR = 0.51; 95% CI: 0.41–0.64], p < 0.0001).	Median OS was not reached (HR = 0.60; 98.89% CI: 0.40–0.89; p = 0.0010)	Results apply to all IMDC subgroups
CLEAR[10]	Lenvatinib–pembrolizumab Lenvatinib–everolimus Sunitinib	355 357 357	71% 53.5% 36.1% (95% CI: 1.69–2.29)	16.1% 9.8% 4.2%	23.9 (20.8–27.7) 14.7 (11.1–16.7) 9.2 (6.0–11), HR (lenvatinib– pembrolizumab vs. sunitinib) = 0.39, 95% CI: 0.32–0.49, p < 0.001	Not reached	Survival with lenvatinib–pembrolizumab significantly longer than sunitinib HR for death 0.66, 95% CI: 0.49–0.88; p = 0.005) OS benefit seen in all subgroups except favorable risk IMDC

Abbreviations: CI, confidence interval; CR, complete response; HR, hazard ratio; IMDC, international metastatic renal cell carcinoma (mRCC) database criteria; ITT, intent to treat; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; PDL1, program cell death ligand-1; TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor.

Out of the six first-line phase-III studies, four have shown OS advantage of IO over sunitinib. The study of ipilimumab–nivolumab, pembrolizumab–axitinib, and lenvatinib–pembrolizumab has shown OS advantage in intermediate- and poor-risk IMDC groups, cabozantinib–nivolumab has shown survival advantage across three IMDC groups. Programmed cell death ligand-1 (PDL1) testing has been done in various studies, but none of the studies have shown correlation of PDL1 status with survival.[5] [6] [9] [10]

Publikationsverlauf

Artikel online veröffentlicht:
03. Februar 2022

• References

• 1 Motzer RJ, Hutson TE, Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356 (02) 115-124
• 2 Motzer RJ, Hutson TE, Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (22) 3584-3590
• 3 Sternberg CN, Davis ID, Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28 (06) 1061-1068
• 4 Choueiri TK, Hessel C, Halabi S. et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 2018; 94: 115-125
• 5 Motzer RJ, Tannir NM, McDermott DF. et al. CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378 (14) 1277-1290
• 6 Rini BI, Plimack ER, Stus V. et al. KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380 (12) 1116-1127
• 7 Motzer RJ, Penkov K, Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380 (12) 1103-1115
• 8 Rini BI, Powles T, Atkins MB. et al. IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393 (10189) 2404-2415
• 9 FDA Approves nivolumab plus cabozantinib for advanced renal cell carcinoma. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma. Accessed February 23, 2021
• 10 Motzer R, Alekseev B, Rha SY. et al. CLEAR Trial Investigators. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021; 384 (14) 1289-1300
• 11 Tannir NM, McDermott DF, Escudier B. et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab 1 ipilimumab (N1I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma aRCC. J Clin Oncol 2020; 38: 609
• 12 McDermott DF, Lee J-L, Bjarnason GA. et al. Open-label, single-arm phase ii study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma. J Clin Oncol 2021; 39 (09) 1020-1028
• 13 Pembrolizumab plus axitinib outperforms sunitinib in patients with metastatic renal cell carcinoma. KEYNOTE-426 data from patients enrolled in Eastern Asia is consistent with that of the overall population. Available at: https://www.esmo.org/oncology-news/pembrolizumab-plus-axitinib-outperforms-sunitinib-in-patients-with-metastatic-renal-cell-carcinoma. Accessed February 23, 2021
• 14 Quhal F, Mori K, Bruchbacher A. et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol 2021; (e-pub ahead of print). doi: DOI: 10.1016/j.euo.2021.03.001.
• 15 Ambavane A, Yang S, Atkins MB. et al. Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. Immunotherapy 2020; 12 (01) 37-51
• 16 Watson TR, Gao X, Reynolds KL, Kong CY. Cost-effectiveness of pembrolizumab plus axitinib vs nivolumab plus ipilimumab as first-line treatment of advanced renal cell carcinoma in the US. JAMA Netw Open 2020; 3 (10) e2016144
• 17 Dudani S, Graham J, Wells JC. et al. First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium. Eur Urol 2019; 76 (06) 861-867
• 18 McGregor BA, Lalani A-K, Xie W. et al. Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC. Ann Oncol 2018; 29 (Suppl. 08) VIII311
• 19 Ornstein MC, Pal SK, Wood LS. et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol 2019; 20 (10) 1386-1394
• 20 Buonerba C, Dolce P, Iaccarino S. et al. Outcomes associated with first-line anti-PD-1/PD-L1 agents vs. sunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and meta-analysis. Cancers (Basel 2020; 12 (02) E408
• 21 Bex A, Mulders P, Jewett M. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2019; 5 (02) 164-170
• 22 Méjean A, Ravaud A, Thezenas S. et al. etal. Sunitinib alone or after nephrectom in metastatic renal cell carcinoma. N Engl J Med 2018; 379 (05) 417-427